TGFB1 and head and neck squamous cell carcinoma: To determine the potential of p38 inhibitor SB202190 in HNSCC treatment, SCC-25, and UPCI-SCC090 cells were stimulated for different periods with TGF-beta-1 and SB202190-inhibitor (concentration 9–25 μM) and prepared for Western blot analysis.